Category - Developments

Developments

CytoSorbents appears to validate Sigyn’s therapeutic strategy

CytoSorbents (NASDAQ:CTSO) has received a research grant from a division of the NIH to test the ability of its existing polymers to remove cytokines and lipopolysaccharide (LPS) endotoxin from septic porcine plasma, a...

November 10, 2022

Developments

IntelGenx in feasibility, development agreement for CBD-infused VetaFilm for pets

IntelGenx (TSX:IGX; OTCQB:IGXT) entered into a feasibility study and development agreement with an undisclosed animal health company focused on advancing a VetaFilm-based oral film formulation containing CBD for use in...

November 9, 2022

Developments

Hepion to present rencofilstat’s poly-indication potential at antifibrotic summit

Hepion Pharmaceuticals’ (NASDAQ:HEPA) chief scientific officer, Daren Ure, Ph.D., will present data highlighting the poly-indication potential of the company’s lead drug candidate, rencofilstat, at the upcoming 6th...

November 7, 2022

Developments

Hepion to present 2 posters at upcoming AASLD liver meeting

Hepion Pharmaceuticals (NASDAQ:HEPA) is presenting two poster presentations highlighting its lead drug candidate, rencofilstat, at the Liver Meeting 2022, to be hosted by the American Association for the Study of Liver...

November 2, 2022

Developments

Rhythm to launch Phase 3 hypothalamic obesity trial in early 2023

Rhythm Pharmaceuticals (NASDAQ:RYTM) plans to initiate a Phase 3 clinical trial in acquired hypothalamic obesity in early 2023, following recent discussions with the FDA. The Phase 3 clinical trial will enroll 120...

November 2, 2022

Developments

IntelGenx files for U.S. oral film patent improving cannabinoid onset of action

IntelGenx (TSX:IGX; OTCQB:IGXT) filed a new provisional patent application with the United States Patent and Trademark Office (USPTO) entitled, “Advanced Oral Film Formulations.” The patent application...

November 2, 2022

Developments

Atossa to acquire stake in Dynamic Cell Therapies

Atossa Therapeutics (NASDAQ:ATOS) is acquiring 19.99% of the capital stock of closely-held Dynamic Cell Therapies for $2-million, in addition to $3-million previously paid to Dynamic, “This investment in Dynamic...

November 1, 2022

Developments

Rhythm Pharma gets FDA breakthrough status in hypothalamic obesity

Rhythm Pharmaceuticals’ (NASDAQ:RYTM) setmelanotide received breakthrough therapy designation from the FDA for the treatment of hypothalamic obesity. Hypothalamic obesity is a rare, acquired form of extreme obesity that...

November 1, 2022

Developments

SeaStar Medical completes merger with LMF Acquisition Opportunities

SeaStar Medical completed a business combination with LMF Acquisition Opportunities (NASDAQ:LMAO), a special purpose acquisition company sponsored by LM Funding America (NASDAQ:LMFA). The combined company was renamed...

October 28, 2022

Developments

OpSens starts SavvyWire study in Europe

OpSens (TSX:OPS; OTCQX:OPSSF) announced the successful completion of the first cases in a clinical study, named SAFE-TAVI, studying SavvyWire left ventricular rapid pacing in transcatheter aortic valve replacement...

October 26, 2022

Category - Developments

CytoSorbents appears to validate Sigyn’s therapeutic strategy

IntelGenx in feasibility, development agreement for CBD-infused VetaFilm for pets

Hepion to present rencofilstat’s poly-indication potential at antifibrotic summit

Hepion to present 2 posters at upcoming AASLD liver meeting

Rhythm to launch Phase 3 hypothalamic obesity trial in early 2023

IntelGenx files for U.S. oral film patent improving cannabinoid onset of action

Atossa to acquire stake in Dynamic Cell Therapies

Rhythm Pharma gets FDA breakthrough status in hypothalamic obesity

SeaStar Medical completes merger with LMF Acquisition Opportunities

OpSens starts SavvyWire study in Europe

General

More